OPINION Inflammation in bone physiology and pathology
INTRODUCTION
Tissue regeneration is a biological process appreciated since the Bronze Age, from the ancient Greek myth of Prometheus and his punishment for deceiving the gods and protecting mankind. In the Greek myth, an eagle fed from his liver each day, but the liver regenerated overnight. Although, Prometheus is a mythical creature, liver regeneration in humans is a scientific fact. Indeed epimorphic regeneration occurs in certain animals, such as salamanders and frogs, which are able to regenerate limbs, tails, jaws, and eye lenses. In mammals, deer can regenerate their antlers and mouse their ears. These unusual regenerative properties of certain tissues are a logical adaptation of organisms that are likely to be injured. Specifically, the liver is the main detoxifying organ of the body and is likely to be injured by ingested toxins. Similarly, the skeleton is likely to be fractured which necessitates the ability of fractured bone to regenerate and undergo repair. Apart from fracture healing which is most commonly observed, bone regeneration has also been observed in humans after amputations, especially in children.
Clinical evidence
The ability of bone to regenerate after congenital transdiaphyseal amputation has been recognized since the 1940s and includes numerous case reports of digital phalanx regeneration and a more striking skeletal condition unique to children, known as juvenile amputee overgrowth (JAO). This unique pathological condition is characterized by the growth of a skeletal spike that, in extreme cases, perforates the soft tissue envelope [1] . JAO is certainly no myth and has a prevalence of up to 35% in pediatric amputees and its cellular and molecular mechanisms underlying this phenomenon remain undetermined. A wide range of surgical procedures have been proposed for the management of JAO. Occlusion of the medullary canal appears to significantly retard the progression of JAO and is the current treatment of choice with the best reported results occurring with the use of autogenous bone graft [2, 3] . Therefore, current thinking has focused on the progenitor cells and cytokines such as tumour necrosis factor (TNF), Interleukin (IL)-23, IL-17, and Transforming Growth Factorb that are present within the medullary canal and their interplay under inflammatory conditions with inflamed tissue (Fig. 1) . The notion that circulatory cells are able to contribute to bone formation is not observed only in JAO. Interestingly, recent reports suggest that cells with osteogenic potential can be found in a variety of tissues and circulating cells of hematopoietic origin can serve as osteogenic precursors at remote sites of tissue inflammation [4] . This study shows that CD45 þ hematopoietic-derived circulating osteogenic precursor cells with osteogenic potential migrate to inflammatory sites, where they increase heterotopic bone formation in patients with fibrodysplasia ossificans progressiva (FOP). FOP is an extremely rare autosomal dominant genetic disorder of connective tissue defined by progressive, disabling, heterotopic skeletogenesis in predictable anatomic patterns [5] . Histopathologic analysis of FOP lesions have also revealed an extended inflammatory infiltrate consisting of monocytes and lymphocytes that are commonly associated with pathology and more importantly
KEY POINTS
Inflammation regulates bone loss in pathological conditions (rheumatoid arthritis).
Inflammation regulates bone formation in physiological conditions (fracture repair).
Inflammation may recruit different precursor cells and pathways than those observed in physiological bone remodeling. Increased inflammation in arthritis or after amputation and trauma has always been linked with bone loss via osteoclast activation, and many laboratories have studied this phenomenon extensively in autoimmune diseases but the role of inflammation in bone formation is less clear and not well defined. Approximately, two million people have limb amputations in the United States because of disease or injury with more than 185 000 new amputations every year. The ability to promote epimorphic regeneration, or the regrowth of a biologically based digit or limb, would radically change the prognosis for amputees. However, the significance and impact of understanding molecular pathways that regulate physiological and pathological bone remodeling is far greater and more far-reaching than the amputee populations. In fact, the ability to harness inflammatory signals to regenerate bone may enable the understanding of tissue repair mechanisms that can be applied to a large number of tissues with fundamental benefits.
The osteoclast and the osteoblast are the two main cell types that regulate bone remodeling within the bone. They work in tandem, exhibiting opposing functions; to remove and replace bone, respectively. Under physiological conditions, osteoblasts secrete macrophage colony-stimulating factor (M-CSF) which signals through the tyrosine kinase receptor macrophage colony-stimulating factor receptor (Csf1r), which is ubiquitously expressed early during myeloid lineage commitment, and its expression is maintained on nearly all mononuclear phagocytic cells [7] . The differentiation of osteoclast precursors is regulated by the receptor activator of nuclear factor k-B ligand (RANKL) [8] . RANKL-mediated osteoclast differentiation depends on the RANK receptor, which is upregulated by M-CSF in early stage osteoclast precursors [9] . M-CSF activity generates a specific myeloid subset that expresses both Csf1r and Rank. This Csf1r þ /Rank þ myeloid precursor is destined to become a terminally differentiated osteoclast on bone surfaces upon stimulation with M-CSF and RANKL. Osteoblasts control the availability of M-CSF and RANKL to osteoclast precursors and also regulate the production and secretion of osteoprotegerin (OPG). OPG is a soluble decoy receptor for RANKL; thus, the main determinants of osteoclastogenesis are the relative concentrations of M-CSF, RANKL, and OPG which regulate a network of gene transcriptions as previously reviewed [10] . The coupling between the osteoblast and the osteoclast at the bone surface, balance bone formation and resorption and maintain bone homeostasis by removing mature bone tissue, following fractures or microfractures, through bone resorption and replacing it with new bone tissue by a process called ossification. The amount of resorption and ossification is, therefore, tightly linked to the number and activity of osteoclasts and osteoblasts and their regulation makes it a necessary event for bone homeostasis and fracture repair [11] . Under inflammatory conditions such as autoimmune diseases, these pathways seem to be disturbed. [12, 13] . This chronic inflammation leads to secretion of a plethora of proinflammatory cytokines and RANKL, which are primarily responsible for the activation of osteoclasts and the subsequent bone destruction.
Inflammatory bone remodeling
Rheumatoid arthritis is a chronic inflammatory autoimmune disease that exhibits various clinical manifestations, including synovial inflammation and bone loss. Immune cells such as T helper cell17 cells, B cells, macrophages, neutrophils, mast cells, and fibroblast-like synoviocytes are critical for inducing and maintaining synovial inflammation in rheumatoid arthritis pathology
Transcriptional regulation of bone formation
RANKL regulates a number of transcription factors including Nuclear factor kappa-B (NFkB), which is critical in osteoclast differentiation [10, 14] . The Inhibitor of nuclear factor kappa-B kinase (IKK) kinase complex, comprised of two kinases (IKKa and IKKb) and a regulatory subunit, NF-kappa-B essential modulator/IKKg is the core element of the NF-kB cascade. This can be activated by RANKL and TNF in both physiological and pathological (inflammatory) conditions to regulate osteoclastogenesis [15] . Interestingly, the same complex seems to have dramatic effects in the regulation of bone formation in osteoblasts [16] . The roles of NFkB transcriptional regulation are diverse and expand in many different cell types that regulate numerous cellular processes. Their functions in bone remodeling include physiological (RANKL) and pathological (TNF)-induced bone loss via osteoclastogenesis and bone formation via the osteoblasts, which have been reviewed elsewhere [17] .
Although RANKL is the most potent osteoclastogenic signal in the aforementioned Csf1r þ /Rank þ myeloid populations, osteoclasts have also been generated under inflammatory conditions in RANK À/À mice [17-19,20 && ]. In these alternative pathways of osteoclastogenesis that is independent of RANKL, it is clearly evident that a few proinflammatory cytokines including TNF [21, 22] and IL-23 [23] regulate the activation of calcium signaling and nuclear factor of activated T-cells cytoplasmic 1 (NFATc1). NFATc1
À/À cells are unable to generate osteoclasts, despite normal development into the monocyte/macrophage lineage, highlighting the specific needs of osteoclastogenesis [24] . NFATc1 is a transcription factor activated by calcium signaling, as Ca 2þ activates calcineurin, which in turn dephosphorylates multiple phosphoserines on NFAT, leading to its nuclear translocation and activation. NFATc1 is responsible for the regulation of genes related to osteoclast function as well as numerous genes nonessential to osteoclast function [25, 26] ; therefore, the significance of this pathway may extend beyond our current understanding. This is particularly important as other research groups, paradoxically, have observed a role of NFATc1 in bone formation. Although NFATc1 in osteoclasts induces bone loss in osteoblasts, NFATc1 induces bone formation as mice expressing a constitutively nuclear NFATc1 variant (NFATc1nuc) develop high bone mass [27] . Surprisingly, NFATc1nuc mice have massive osteoblast overgrowth and enhanced osteoblast proliferation [27] . Although Runx2/Cbfa1 is considered as the major transcription factor to trigger activation of osteoblast-specific genes [28] , at least in one report, NFATc1 regulates bone mass via the osteoblast. The emerging importance of NFATc1 in bone remodeling is because of the fact that Runx2/Cbfa1 is expressed restrictively in osteoblasts, whereas NFATc1 is expressed in both osteoblasts and osteoclasts. More importantly, if indeed that is the case, it seems that NFATc1 transcription factor can regulate bone formation and bone loss in both cell types. This is of particular importance as proinflammatory cytokines such as IL-23 and TNF can induce NFATc1 [22, 23] .
The notion that inflammation is required for bone regeneration is supported by various observations, most importantly the impaired fracture healing in TNF-deficient mice [29] . The ability of inflammatory signals to induce bone formation is also corroborated by the findings that deregulated bone formation occurs at erosion sites in inflammatory arthritis although it is not clear whether this is a coupling effect where increased bone loss is leading to increased bone formation or whether it is a directly inflammation-induced bone formation.
Paradoxical observations
The induction of bone overgrowth in JAO is indeed puzzling and reconciling the paradox of increased bone formation under inflammatory conditions is challenging. The significant overlaps in transcriptional regulation between osteoclasts, osteoblasts, and T cells, by common transcription factors, NFkB and NFATc1 can only partly explain the clinical observations in JAO. This is because although osteoblasts and osteoclasts express TNF and IL-23 receptors the presence of immunoreceptors such as DNAX-activating protein of 12 kda (DAP12) and myeloid DAP12 associated lectin 1 (MDL-1) is critical for NFATc1 stimulation. Indeed, a complex interplay between adaptors and immunoreceptors, including DAP10, DAP12, and MDL-1 can relay activation signals that regulate osteoclastogenesis and bone mineral density [30] (Fig. 2) . This is of immense importance as those immunoreceptors are only expressed in hematopoietic cells and not mesenchymal cells. The assumption that circulating cells are of hematopoietic origin, can be manipulated to both bone resorbing and bone forming cells is supported by some evidence [4] . However, before we can explain a paradox with yet another paradox, more experiments in circulating cells need to be performed and a thorough investigation to dissect which cell type responds to inflammation-induced NFkB/NFATc1 activation is much needed. Whether bone formation on hematopoietic precursor cells is possible or not, the certainty is that the molecular mechanisms of inflammatory bone regenerations elude us.
IL-23/IL17 in bone regeneration
Nonconventional gd T cell receptor (TCR) þ cells are a small (<5% in human peripheral blood) subset of T cells that straddles between the adaptive and innate immune responses and exhibit a high percentage of IL-23R þ cells ($38%), compared with other innate cells (4-6%) [31, 32] . Studies on fracture healing have shown differences in the biomechanical properties of fracture repair, upregulation of cell adhesion molecules in osteoblasts and secretion of inflammatory cytokines at the regenerative site in the absence of gd TCR þ cells, suggesting that a more central role of gd T cells in fracture healing [33] . Other recent studies have specifically shown that Vg6 þ gd T cells are the major source of IL-17A in bone regeneration and the action of IL-17 is responsible for enhanced bone formation in a drill-hole injury animal model [34 && ]. The contribution of IL-23 in the differentiation and expansion of IL-23R þ T-cell subsets that produce IL-17 to enhance bone formation is also corroborated by other groups. Other groups have also shown that proinflammatory cytokines IL-17 and TNF have the ability to induce gene expression of genes Wingless related integration site 5a, Bone morphogenic protein2, and Runt-related transcription factor2, associated and required for osteoblast differentiation in isolated synoviocytes of arthritic patients [35 & ].
CONCLUSION
The role of inflammation has been closely associated with bone loss and osteoclastogenesis, however, it becomes more clear that inflammation has a strong role in bone formation. The same proinflammatory cytokines that have been studied in the context of bone loss in animal models of arthritis are now being studied in bone fracture/repair models. The dual capacities of many transcription factors, including NFkB and NFATc1 that regulate these processes, suggest that adaptor or transducer molecules may fine tune these regulatory elements that need to be identified. Moreover, the specific cell subtypes that give rise to terminally differentiated osteoclasts and osteoblasts need to be better defined [36] . Once we have overcome these obstacles, the exciting prospects of bone regeneration will be realized as a therapeutic approach. For now, although bone regeneration may not be a myth, it certainly merits further investigation.
